EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

RAPT has discovered and advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

Abdominal aortic aneurysm (AAA) is a degenerative lesion characterized by structural disruption of the abdominal aortic wall and progressive dilatation into a pulsatile mass. AAA is strongly ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

CytoDyn gets US FDA nod to begin phase II oncology trial of leronlimab in patients with r/r microsatellite stable colorectal cancer: Vancouver, Washington Wednesday, November 6, 2 ...

StatementPentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals 04.11.2024 / 17:26 CET/CESTThe issuer is solely responsible for the content of this ...

VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company ...

Ding, B. , Wu, Y. , Zhang, Y. and Li, Y. (2024) CXCL10 Induces Lytic Reactivation of EBV through EXTL 1. Advances in ...

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology ...

Mechanistically, the deletion of Cmtm3 reduced the expression of Toll-like receptor 4 (TLR4) on neutrophils, leading to a decrease in the expression of C-X-C motif chemokine receptor 2 (CXCR2) on the ...